News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
736,691 Results
Type
Article (44479)
Company Profile (279)
Press Release (691915)
Multimedia
Podcasts (100)
Webinars (22)
Section
Business (206033)
Career Advice (2332)
Deals (35810)
Drug Delivery (141)
Drug Development (82275)
Employer Resources (184)
FDA (16725)
Job Trends (15115)
News (349496)
Policy (33194)
Tag
2027 BioCapital Elite (1)
2027 Bio NC Standard (1)
2027 Biotech Bay Standard (2)
2027 Genetown Elite (2)
2027 Genetown Standard (1)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (5)
Academia (2673)
Accelerated approval (45)
Adcomms (30)
Allergies (171)
Alliances (49931)
ALS (207)
Alzheimer's disease (1803)
Antibody-drug conjugate (ADC) (430)
Approvals (17045)
Artificial intelligence (645)
Autoimmune disease (261)
Automation (52)
Bankruptcy (364)
Best Places to Work (11715)
BIOSECURE Act (21)
Biosimilars (221)
Biotechnology (189)
Bladder cancer (184)
Brain cancer (70)
Breast cancer (728)
Cancer (5698)
Cardiovascular disease (467)
Career advice (1972)
Career pathing (41)
CAR-T (324)
CDC (58)
Celiac Disease (3)
Cell therapy (862)
Cervical cancer (46)
Clinical research (71120)
Collaboration (2028)
Company closure (6)
Compensation (1333)
Complete response letters (88)
COVID-19 (2808)
CRISPR (107)
C-suite (1073)
Cystic fibrosis (152)
Data (7562)
Decentralized trials (3)
Denatured (29)
Depression (164)
Dermatology (76)
Diabetes (587)
Diagnostics (6979)
Digital health (53)
Diversity (12)
Diversity, equity & inclusion (46)
Drug discovery (313)
Drug pricing (216)
Drug shortages (35)
Duchenne muscular dystrophy (278)
Earnings (91698)
Editorial (70)
Employer branding (22)
Employer resources (159)
Events (119771)
Executive appointments (1070)
FDA (20356)
Fibrodysplasia Ossificans Progressiva (7)
Friedreich's ataxia (15)
Frontotemporal dementia (34)
Funding (1688)
Gene editing (230)
Generative AI (56)
Gene therapy (698)
GLP-1 (1097)
Government (4832)
Grass and pollen (6)
Guidances (405)
Healthcare (19138)
HIV (78)
Huntington's disease (57)
IgA nephropathy (95)
Immunology and inflammation (297)
Immuno-oncology (87)
Indications (176)
Infectious disease (3147)
Inflammatory bowel disease (210)
Inflation Reduction Act (15)
Influenza (135)
Intellectual property (286)
Interviews (400)
IPO (16732)
IRA (53)
Job creations (3706)
Job search strategy (1626)
JPM (61)
Kidney cancer (20)
Labor market (100)
Layoffs (576)
Leadership (40)
Legal (8072)
Liver cancer (100)
Longevity (32)
Lung cancer (760)
Lymphoma (421)
Machine learning (59)
Management (62)
Manufacturing (1017)
MASH (183)
Medical device (14049)
Medtech (14147)
Mergers & acquisitions (20304)
Metabolic disorders (1518)
mRNA (205)
Multiple sclerosis (185)
NASH (18)
Neurodegenerative disease (416)
Neuropsychiatric disorders (110)
Neuroscience (3306)
Neurotech (1)
NextGen: Class of 2026 (6624)
Non-profit (4570)
Now hiring (76)
Obesity (722)
Opinion (316)
Ovarian cancer (208)
Pain (252)
Pancreatic cancer (290)
Parkinson's disease (355)
Partnered (33)
Patents (585)
Patient recruitment (648)
Peanut (62)
People (59864)
Pharmaceutical (59)
Pharmacy benefit managers (34)
Phase 1 (22111)
Phase 2 (31314)
Phase 3 (23363)
Pipeline (7952)
Policy (331)
Postmarket research (2621)
Preclinical (9430)
Press Release (64)
Prostate cancer (291)
Psychedelics (57)
Radiopharmaceuticals (319)
Rare diseases (1057)
Real estate (6013)
Recruiting (73)
Regulatory (25560)
Reports (59)
Research institute (2464)
Resumes & cover letters (394)
Rett syndrome (36)
RNA editing (21)
RSV (90)
Schizophrenia (179)
Series A (281)
Series B (207)
Service/supplier (11)
Sickle cell disease (110)
Special edition (23)
Spinal muscular atrophy (170)
Sponsored (48)
Startups (3687)
State (2)
Stomach cancer (19)
Supply chain (128)
Tariffs (95)
The Weekly (68)
Vaccines (1113)
Venture capital (106)
Weight loss (482)
Women's health (120)
Worklife (21)
Date
Today (113)
Last 7 days (761)
Last 30 days (2870)
Last 365 days (30459)
2026 (10686)
2025 (30425)
2024 (35469)
2023 (40322)
2022 (51458)
2021 (56021)
2020 (54494)
2019 (47043)
2018 (35439)
2017 (32495)
2016 (31920)
2015 (37938)
2014 (31712)
2013 (26701)
2012 (28981)
2011 (29612)
2010 (27717)
Location
Africa (793)
Alabama (91)
Alaska (7)
Arizona (345)
Arkansas (14)
Asia (40136)
Australia (6662)
California (12861)
Canada (3675)
China (1308)
Colorado (548)
Connecticut (556)
Delaware (390)
Europe (87219)
Florida (1926)
Georgia (413)
Hawaii (3)
Idaho (62)
Illinois (1029)
India (88)
Indiana (594)
Iowa (23)
Japan (514)
Kansas (129)
Kentucky (52)
Louisiana (39)
Maine (75)
Maryland (1549)
Massachusetts (9152)
Michigan (355)
Minnesota (701)
Mississippi (6)
Missouri (145)
Montana (33)
Nebraska (29)
Nevada (139)
New Hampshire (85)
New Jersey (3396)
New Mexico (29)
New York (3382)
North Carolina (1644)
North Dakota (8)
Northern California (6401)
Ohio (382)
Oklahoma (23)
Oregon (42)
Pennsylvania (2584)
Puerto Rico (28)
Rhode Island (50)
South America (1157)
South Carolina (85)
South Dakota (2)
Southern California (5065)
Tennessee (207)
Texas (2030)
United States (45451)
Utah (385)
Vermont (1)
Virginia (308)
Washington D.C. (81)
Washington State (1031)
West Virginia (4)
Wisconsin (122)
Wyoming (2)
736,691 Results for "pressure point inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Earnings
Novartis’ sales dip as generics pressure intensifies, radioequivalents loom
Executives insist Novartis will return to growth in the second half, but for Q1 2026, generic erosion drove a 5% drop in revenue, including a 46% nosedive for blockbuster heart failure drug Entresto.
April 28, 2026
·
2 min read
·
Tristan Manalac
Cardiovascular disease
Kardigan Blood Pressure Drug Proves Hypothesis Despite Split Phase 2 Readout
While tonlamarsen missed one of two co-primary endpoints, Kardigan says the drug has shown a clinically meaningful effect on blood pressure, supporting advancement into Phase 2b.
March 30, 2026
·
2 min read
·
Annalee Armstrong
Mergers & acquisitions
Pharma Is Ravenous for M&A Action but Late-Stage Supply Dwindles
Whether happening in public or private, biopharma M&A is fiercer than ever. Experts point to patent pressures, herd mentality and a declining stock of available biotechs with mature assets.
March 11, 2026
·
5 min read
·
Annalee Armstrong
Press Releases
Lighthouse Pharmaceuticals Closes $12 Million Series A Financing Led by Double Point Ventures
April 28, 2026
·
2 min read
Opinion
2026 Could Mark a Turning Point for American Innovation
The current state of political affairs in the U.S. does not bode well for the direction of that turn. The country is at real risk of losing its long-held lead in biotech innovation.
February 16, 2026
·
4 min read
·
John Stanford
Press Releases
Blue Genes Partners with RxSense to Deliver Actionable PGx at the Point of Adjudication
February 23, 2026
·
3 min read
Press Releases
TriSalus Life Sciences Announces Publication Demonstrating Enhanced Delivery and Immune Activation with Nelitolimod Delivered with Pressure-Enabled Drug Delivery in Liver Tumor Models
March 18, 2026
·
8 min read
Sickle cell disease
Novo’s late-stage sickle cell win piles pressure on competitors
Novo Nordisk’s etavopivat elicited a 27% drop in vaso-occlusive crises and 48.7% hemoglobin response after 24 weeks, creating “separation amongst PK class candidates,” Truist analysts said on Monday. Novo plans to seek FDA approval in the back half of 2026.
April 20, 2026
·
2 min read
·
Tristan Manalac
Manufacturing
Surge in Radiopharmaceutical R&D Puts Pressure on Unique Supply Chain
The industry’s ability to generate a return on billions of dollars of investment rests on a heavily regulated supply chain defined by time-pressured logistics.
November 18, 2025
·
4 min read
·
Nick Paul Taylor
Press Releases
SEQSTER Launches 1-Click Sites™ to Transform Clinical Sites into Research-Ready Data Collection Points: Names BioIVT as First Deployment Partner
April 17, 2026
·
4 min read
1 of 73,670
Next
